CA2079901A1 - Anticorps monoclonaux anti-igm, procede de fabrication et mode d'utilisation et hybridomes servant a les produire - Google Patents

Anticorps monoclonaux anti-igm, procede de fabrication et mode d'utilisation et hybridomes servant a les produire

Info

Publication number
CA2079901A1
CA2079901A1 CA002079901A CA2079901A CA2079901A1 CA 2079901 A1 CA2079901 A1 CA 2079901A1 CA 002079901 A CA002079901 A CA 002079901A CA 2079901 A CA2079901 A CA 2079901A CA 2079901 A1 CA2079901 A1 CA 2079901A1
Authority
CA
Canada
Prior art keywords
antibody
monoclonal antibody
igm
conjugate
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002079901A
Other languages
English (en)
Inventor
Michael G. Rosenblum
Nicholas J. Donato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2079901A1 publication Critical patent/CA2079901A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002079901A 1990-04-27 1991-04-24 Anticorps monoclonaux anti-igm, procede de fabrication et mode d'utilisation et hybridomes servant a les produire Abandoned CA2079901A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51597490A 1990-04-27 1990-04-27
US515,974 1990-04-27

Publications (1)

Publication Number Publication Date
CA2079901A1 true CA2079901A1 (fr) 1991-10-28

Family

ID=24053580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002079901A Abandoned CA2079901A1 (fr) 1990-04-27 1991-04-24 Anticorps monoclonaux anti-igm, procede de fabrication et mode d'utilisation et hybridomes servant a les produire

Country Status (12)

Country Link
EP (1) EP0538267A4 (fr)
JP (1) JPH06504424A (fr)
CN (1) CN1057072A (fr)
CA (1) CA2079901A1 (fr)
IE (1) IE911172A1 (fr)
IL (1) IL97827A0 (fr)
NZ (1) NZ237784A (fr)
PT (1) PT97482B (fr)
RU (1) RU2105062C1 (fr)
TW (1) TW349995B (fr)
WO (1) WO1991017257A1 (fr)
ZA (1) ZA912695B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322562B1 (fr) 2008-09-05 2016-03-30 Sekisui Medical Co., Ltd. Anticorps monoclonal et immunodosage l'utilisant
CN108384761B (zh) * 2018-03-30 2020-08-11 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
CN116143931B (zh) * 2021-11-20 2023-10-31 东莞市朋志生物科技有限公司 一种抗人IgM抗体及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792447A (en) * 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
AU9016591A (en) * 1990-10-25 1992-05-26 Tanox Biosystems, Inc. Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on B cells

Also Published As

Publication number Publication date
PT97482B (pt) 1998-08-31
NZ237784A (en) 1992-09-25
CN1057072A (zh) 1991-12-18
AU7866491A (en) 1991-11-27
RU2105062C1 (ru) 1998-02-20
IE911172A1 (en) 1991-11-06
WO1991017257A1 (fr) 1991-11-14
ZA912695B (en) 1993-02-24
TW349995B (en) 1999-01-11
JPH06504424A (ja) 1994-05-26
EP0538267A4 (en) 1994-06-01
IL97827A0 (en) 1992-06-21
AU650659B2 (en) 1994-06-30
EP0538267A1 (fr) 1993-04-28
PT97482A (pt) 1992-01-31

Similar Documents

Publication Publication Date Title
EP0153114B1 (fr) Anticorps monoclonaux contre le cancer du sein humain, leur production et application, et hybridomes pour leur préparation et production de ces hybridomes
US5629197A (en) Monoclonal anti-human breast cancer antibodies
Mason et al. Preparation of peroxidase: antiperoxidase (PAP) complexes for immunohistological labeling of monoclonal antibodies.
US4450154A (en) Antitumor hybrid and process for the preparation thereof
US5496549A (en) Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis
CA1290266C (fr) Anticorps monoclonaux contre des proteines non reduites et non glycosylees parun enzyme
JPS62215600A (ja) 抗−ヒト卵巣癌免疫毒素及びその使用方法
Ball et al. Isolation and characterization of monoclonal antibodies to (Na++ K+)-ATPase
CA1297048C (fr) Anticorps monoclonaux reagissant avec des formes normales et oncogene de la proteine p21 ras
US6306626B1 (en) Anti-IgM monoclonal antibodies and methods of their use
US4357273A (en) Antitumor protein hybrid and process for the preparation thereof
CA2079901A1 (fr) Anticorps monoclonaux anti-igm, procede de fabrication et mode d'utilisation et hybridomes servant a les produire
US5053492A (en) Immunopurification using monoclonal antibodies to Mojave toxin
AU650659C (en) Monoclonal anti-IgM antibodies, their production and use, and hybridomas for producing the same
JPWO1987003377A1 (ja) グルタチオンｓ−トランスフェラ−ゼに対するモノクロ−ナル抗体及びその製造法
JPS59134734A (ja) 殺細胞性修飾免疫グロブリン及びその製造方法
Tonevitsky et al. Elimination of murine erythroleukemic stem cells with a novel anti‐erythroid antibody conjugated to ricin a‐chain: A model for studies of bone‐marrow transplantation therapy
CA1253090A (fr) Anticorps monoclonaux contre le cances du sein chez les humains
JP2004091454A (ja) 抗体及びその製造方法並びに抗体を用いた抗原の定量方法
CA2132632A1 (fr) Anticorps diriges contre la zone pellucide et acheminant un agent therapeutique a l'ovaire
NAIEM Preparation of Peroxidase: Antiperoxidase (PAP) Complexes for Immunohistological Labeling of
CA2056118A1 (fr) Anticorps monoclonaux qui lient la proteine fixatrice du mannose
HUMAN FACTOR D1
CA2032757A1 (fr) Anticorps monoclonaux liant (e)-5-(2-bromovinyl)-arabinofuranosylvracil et methode diagnostique basee sur ces anticorps
JPH0320239B2 (fr)

Legal Events

Date Code Title Description
FZDE Discontinued